National Health Act 1953 - Amendment Special Arrangements under subsection 100(1) - Highly specialised drugs program for public hospitals (No. PB 104 of 2009)

Overview

The National Health Act 1953 was enacted to provide a framework for ensuring Australians have access to reliable, timely, and affordable pharmaceutical benefits. The Act established the Pharmaceutical Benefits Scheme (PBS), which is administered by the Commonwealth, to deliver a wide range of medicines to the public. To address specific needs not fully met by the PBS, the Act allows the Minister for Health to make special arrangements under section 100 for providing pharmaceutical products to certain groups, including those receiving treatment in isolated areas or in circumstances where the PBS is inadequate. The Highly Specialised Drugs Program for Public Hospitals, introduced under these special arrangements, ensures that an adequate supply of certain highly specialised drugs is available to patients in public hospitals. This legislative instrument, enacted by the Parliament of Australia, amends the existing arrangements to include additional drugs and modify existing entries, ensuring the program remains responsive to evolving medical needs. The amendments introduced by the instrument, effective from 1 November 2009, include adding new drugs such as lenalidomide and modifying the circumstances under which certain drugs like dornase alfa and etanercept are provided. Additionally, the instrument updates the formatting of drug entries and removes or alters specific drug forms, such as those involving ribavirin and peginterferon alfa-2a. These changes aim to streamline the program and enhance its effectiveness in meeting the therapeutic needs of patients in public hospitals. The process involves recommendations from expert bodies like the Pharmaceutical Benefits Advisory Committee (PBAC) and the Commonwealth/State Highly Specialised Drugs Working Party (HSDWP), ensuring that decisions are evidence-based and consider both clinical and administrative factors.

Scope and Application

The National Health Act 1953, as amended, applies to the provision of pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS) and the administration of highly specialised drugs through the Highly Specialised Drugs Program for Public Hospitals. The Act applies to all Australians, with a particular focus on those residing in isolated areas or receiving medical treatment in circumstances where the PBS does not provide adequate pharmaceutical benefits. The Highly Specialised Drugs Program is designed to ensure an adequate supply of special pharmaceutical products for non-admitted, day admitted, and discharged patients in public hospitals. The scope of the Act includes the declaration of drugs and medicinal preparations under subsection 85(2), with special arrangements for highly specialised drugs provided under section 100 of the Act. The amendments made by the legislative instrument in question adjust the list of drugs and their specific forms available under the Program, as outlined in Schedules 1 to 3 of the instrument. These amendments came into effect on 1 November 2009, refining the eligibility criteria and the specific pharmaceutical products covered under the Highly Specialised Drugs Program. The Pharmaceutical Benefits Advisory Committee (PBAC) and the Commonwealth/State Highly Specialised Drugs Working Party (HSDWP) play integral roles in recommending and evaluating drugs for inclusion in the PBS and the Highly Specialised Drugs Program, respectively.

Key Provisions

The National Health Act 1953, as amended by the legislative instrument PB 104 of 2009, establishes the Highly Specialised Drugs Program for Public Hospitals under section 100(1). This program ensures an adequate supply of special pharmaceutical products for patients receiving treatment in public hospitals as non-admitted, day admitted, or discharge patients. This amendment, which came into effect on 1 November 2009, modifies the previous arrangements under PB 61 of 2009. The changes include the addition of specific drugs and adjustments to their forms and circumstances of use, as detailed in Schedule 1 and Schedule 2 of the instrument. The obligations under this Act require the Minister to ensure the availability of special pharmaceutical products for eligible patients under the Highly Specialised Drugs Program. This includes administering the program in accordance with the amended arrangements, which detail specific drugs and their respective forms. The Pharmaceutical Benefits Advisory Committee (PBAC) and the Commonwealth/State Highly Specialised Drugs Working Party (HSDWP) play key roles in recommending drugs for inclusion in the program. The Minister must also ensure that these recommendations are considered and that the necessary legislative instruments are updated to reflect any changes. Failure to comply with the provisions of the Highly Specialised Drugs Program could result in legal consequences. Although the specific offences and penalties for breach are not detailed in the instrument, non-compliance with provisions related to the provision of pharmaceutical benefits under the National Health Act 1953 may attract penalties under the broader legislative framework. These could include fines or other civil or criminal penalties as prescribed by the relevant legislation. In summary, the amended legislative instrument PB 104 of 2009 updates the Highly Specialised Drugs Program for Public Hospitals to ensure the continued supply of necessary pharmaceutical products for patients receiving treatment in public hospitals. The Minister's obligations include administering the program in accordance with the updated arrangements, and recommendations from the PBAC and HSDWP are integral to this process. While specific penalties for non-compliance are not outlined in this instrument, they may be found within the broader legislative framework governing the National Health Act 1953.